CytoDyn Inc. (CYDY)
CytoDyn Inc. functions as a biotechnology enterprise currently in its clinical development phase. The company primarily concentrates on crafting therapies for a variety of medical conditions, leveraging leronlimab – an innovative humanized monoclonal antibody designed to interact with the CCR5 receptor. This experimental drug is being explored for its potential applications in human immunodeficiency virus (HIV), non-alcoholic steatohepatitis (NASH), various oncological diseases, and coronavirus disease (COVID-19). In addition, leronlimab is undergoing a Phase 1b/2 clinical investigation specifically for metastatic triple-negative breast cancer. Established in 2002, and previously operating as RexRay Corporation, CytoDyn Inc. is headquartered in Vancouver, Washington.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
CytoDyn Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 1.47B shares outstanding
USCytoDyn Inc. functions as a biotechnology enterprise currently in its clinical development phase.
The company primarily concentrates on crafting therapies for a variety of medical conditions, leveraging leronlimab – an innovative humanized monoclonal antibody designed to interact with the CCR5 receptor. This experimental drug is being explored for its potential applications in human immunodeficiency virus (HIV), non-alcoholic steatohepatitis (NASH), various oncological diseases, and coronavirus disease (COVID-19).
In addition, leronlimab is undergoing a Phase 1b/2 clinical investigation specifically for metastatic triple-negative breast cancer. Established in 2002, and previously operating as RexRay Corporation, CytoDyn Inc. is headquartered in Vancouver, Washington.
Leadership
Robert E. Hoffman
Chief Financial Officer
Jacob Lalezari
Chief Executive Officer
Tyler Blok
Chief Legal Officer & Corporate Secretary
Employees
9
Country
US
Sector
Healthcare
Website
cytodyn.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Hoffman Robert E. | Chief Executive Officer | Grant/Award | 2.50M | -- | Oct 20, 2026 |
 Urbach Tanya Durkee | Director | Grant/Award | 574.4K | -- | Mar 20, 2026 |
 SIMES STEPHEN M | Director | Grant/Award | 574.4K | -- | Mar 20, 2026 |
 Ndhlovu Lishomwa C | Director | Grant/Award | 574.4K | -- | Mar 20, 2026 |
 Lalezari Jacob P | Chief Executive Officer | Grant/Award | 4.87M | -- | Mar 20, 2026 |
| Hoffman Robert E. | Chief Executive Officer | Grant/Award | 4.87M | -- | Mar 20, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
DIVERSIFIED TRUST CO | 45.8K | 0.0% | 13F |
Williams Jones Wealth Management, LLC. | 45.0K | 0.0% | 13F |
Next Capital Management LLC | 25.0K | 0.0% | 13F |
HORIZON FINANCIAL SERVICES, LLC | 18.2K | 0.0% | 13F |
Ancora Advisors LLC | 9.5K | 0.0% | 13F |
CAZ INVESTMENTS LP | 4.0K | 0.0% | 13F |
Insiders
- Hoffman Robert E.Chief Executive Officer
- Urbach Tanya DurkeeDirector
- SIMES STEPHEN MDirector
- Ndhlovu Lishomwa CDirector
- Lalezari Jacob PChief Executive Officer
- Dunlap RyanDirector
- Brunke Karen JDirector
- Blok TylerChief Legal Officer
based on 1.47B shares outstanding
US30d Avg
2.61M
60d Avg
2.04M
90d Avg
1.80M